BACKGROUND: Circadian rhythm disturbances in adults with cancer are associated with fatigue, time to relapse, and death. This study of circadian activity rhythms (CAR) of children with acute lymphoblastic leukemia (ALL) on continuation chemotherapy aimed to describe CAR before and after starting dexamethasone, and to determine whether fatigue was associated with less robust CAR. PROCEDURE: This was a secondary analysis of data from a multi-institutional study in which children with ALL aged 5-18 years wore an actigraph for 10 consecutive 24-hour periods, five before and five during dexamethasone therapy. CAR parameters measured by actigraphy were calculated for each 5-day period, including peak activity, MESOR, amplitude, acrophase, and circadian quotient. Fatigue was measured on study days 2, 5, 7, and 10 by parent-report and self-report for children ≥ 7 years. RESULTS: Eighty-two children qualified for CAR analysis, and 87 for analysis of daily peak activity patterns and fatigue. Mean age was 8.8 ± 3.3 years. Peak activity, MESOR, and amplitude significantly decreased during dexamethasone therapy. Children on high-dose dexamethasone (8 or 12 mg/m(2)/d) had significantly higher (better, or more robust) values of several CAR parameters than those on low-dose (6 mg/m(2)/d). There was a significant trend of decreasing daily pattern of peak activity during dexamethasone therapy only. Fatigue increased across the study and was associated with decreasing CAR peak activity, MESOR, and amplitude. CONCLUSIONS: Dexamethasone initiation was associated with a decrease in several CAR parameters, and a significant decrease in the trend of daily peak activity. Fatigue was associated with less robust CAR.
BACKGROUND: Circadian rhythm disturbances in adults with cancer are associated with fatigue, time to relapse, and death. This study of circadian activity rhythms (CAR) of children with acute lymphoblastic leukemia (ALL) on continuation chemotherapy aimed to describe CAR before and after starting dexamethasone, and to determine whether fatigue was associated with less robust CAR. PROCEDURE: This was a secondary analysis of data from a multi-institutional study in which children with ALL aged 5-18 years wore an actigraph for 10 consecutive 24-hour periods, five before and five during dexamethasone therapy. CAR parameters measured by actigraphy were calculated for each 5-day period, including peak activity, MESOR, amplitude, acrophase, and circadian quotient. Fatigue was measured on study days 2, 5, 7, and 10 by parent-report and self-report for children ≥ 7 years. RESULTS: Eighty-two children qualified for CAR analysis, and 87 for analysis of daily peak activity patterns and fatigue. Mean age was 8.8 ± 3.3 years. Peak activity, MESOR, and amplitude significantly decreased during dexamethasone therapy. Children on high-dose dexamethasone (8 or 12 mg/m(2)/d) had significantly higher (better, or more robust) values of several CAR parameters than those on low-dose (6 mg/m(2)/d). There was a significant trend of decreasing daily pattern of peak activity during dexamethasone therapy only. Fatigue increased across the study and was associated with decreasing CAR peak activity, MESOR, and amplitude. CONCLUSIONS:Dexamethasone initiation was associated with a decrease in several CAR parameters, and a significant decrease in the trend of daily peak activity. Fatigue was associated with less robust CAR.
Authors: Valerie E Rogers; Shijun Zhu; Belinda N Mandrell; Sonia Ancoli-Israel; Lianqi Liu; Pamela S Hinds Journal: Support Care Cancer Date: 2019-07-04 Impact factor: 3.603
Authors: Priscilla Vasquez; Johanna Escalante; Kimberly P Raghubar; Lisa S Kahalley; Olga A Taylor; Ida Ki Moore; Marilyn J Hockenberry; Michael E Scheurer; Austin L Brown Journal: Pediatr Blood Cancer Date: 2021-12-10 Impact factor: 3.167
Authors: Shosha H M Peersmann; Martha A Grootenhuis; Annemieke van Straten; Gerard A Kerkhof; Wim J E Tissing; Floor Abbink; Andrica C H de Vries; Jacqueline Loonen; Leontien C M Kremer; Gertjan J L Kaspers; Raphaële R L van Litsenburg Journal: Cancers (Basel) Date: 2022-02-13 Impact factor: 6.639
Authors: Shosha H M Peersmann; Annemieke van Straten; Gertjan J L Kaspers; Adriana Thano; Esther van den Bergh; Martha A Grootenhuis; Raphaële R L van Litsenburg Journal: Trials Date: 2021-04-26 Impact factor: 2.279
Authors: Lindsay M H Steur; Gertjan J L Kaspers; Eus J W Van Someren; Natasha K A Van Eijkelenburg; Inge M Van der Sluis; Natasja Dors; Cor Van den Bos; Wim J E Tissing; Martha A Grootenhuis; Raphaële R L Van Litsenburg Journal: Sleep Date: 2020-06-15 Impact factor: 5.849
Authors: L M H Steur; G J L Kaspers; E J W van Someren; N K A van Eijkelenburg; I M van der Sluis; N Dors; C van den Bos; W J E Tissing; M A Grootenhuis; R R L van Litsenburg Journal: Support Care Cancer Date: 2020-04-13 Impact factor: 3.603
Authors: Lauren C Daniel; Raphaele R L van Litsenburg; Valerie E Rogers; Eric S Zhou; Sarah J Ellis; Claire E Wakefield; Robyn Stremler; Lisa Walter; Valerie McLaughlin Crabtree Journal: Psychooncology Date: 2019-11-03 Impact factor: 3.955